期刊文献+

慢性阻塞性肺疾病急性加重期患者规范化痰诱导安全性的初步研究 被引量:45

Safety of sputum induction in subjects with acute exacerbations of chronic obstructive pulmonary disease
原文传递
导出
摘要 目的探讨慢性阻塞性肺疾病急性加重期(AECOPD)患者进行高渗盐水痰诱导的安全性。方法制定规范化操作流程,对22例重度、极重度AECOPD患者进行痰诱导,在诱导过程中严密监测患者第一秒用力呼气容积(FEV1)和脉搏容积血氧饱和度(SpO2)的变化。结果22例AECOPD患者在诱导前SpO2为(93.8±0.9)%,结束时SpO2为(91.7±0.8)%,较基础值下降了(2.1±0.4)%(P<0.01),结束后10min,SpO2恢复至基础值水平;诱导前FEV1为(0.70±0.19)L,结束时为(0.62±0.17)L,FEV1较基础值下降了(12.3±3.1)%(P=0.027),结束后10min,FEV1恢复至基础值水平。共有19例患者渡过了整个痰诱导过程,成功率为86%。结论在严密监控下,使用规范化的痰诱导流程,痰诱导法对AECOPD患者是一种比较安全的方法。 Objective To evaluate the safety of sputum induction in subjects with acute exacerbations of chronic obstructive pulmonary disease(AECOPD). Methods Twenty-two patients with AECOPD were enrolled in the study. All subjects inhaled a mist of 3% hypertonic saline solution and the forced expiratory volume in one second(FEV_1) and pulse oxygen saturation(SpO_2) were measured during the procedure. Results A significant fall in SpO_2 and FEV_1 was found during sputum induction by inhalation of 3% hypertonic saline solution. Mean decline in SpO_2 during sputum induction was (2.1±0.4)%(P<0.01) and recovered within 10 min after cessation of sputum induction. Mean decline in FEV_1 during sputum induction was (12.3±3.1)%(P=0.027),an absolute fall of (0.11±0.03)L,and the FEV_1 returned to the baseline in all subjects within 10 min after cessation of sputum induction. The sputum induction was successful in 19 of the 22(86%) patients. Conclusion The use of a standardized sputum induction protocol is relatively safe in sampling the lower airways in patients with AECOPD.
出处 《中华结核和呼吸杂志》 CAS CSCD 北大核心 2005年第4期238-241,共4页 Chinese Journal of Tuberculosis and Respiratory Diseases
基金 广东省自然科学基金资助项目(04009385) 广东省医学科研基金资助项目(A2004188)
  • 相关文献

参考文献12

  • 1Pin I,Gibson PG,Kolendowicz R,et al. Use of induced sputum cell counts to investigate airway inflammation in asthma. Thorax,1992,47:25-29.
  • 2Sutherland ER,Pak J,Langmack EL,et al. Safety of sputum induction in moderate-to-severe chronic obstructive pulmonary disease. Respir Med,2002,96:482-486.
  • 3Fabbri LM,Hurd SS,GOLD Scientific Committee. Global strategy for the diagnosis,management and prevention of COPD:2003 update. Eur Respir J,2003,22:1-2.
  • 4Celli BR,MacNee W, ATS/ERS Task Force. Standards for the diagnosis and treatment of patients with COPD:a summary of the ATS/ERS position paper. Eur Respir J,2004,23:932-946.
  • 5Bach PB,Brown C,Gelfand SE,et al. Management of acute exacerbations of chronic obstructive pulmonary disease:a summary and appraisal of published evidence. Ann Intern Med,2001,134:600-620.
  • 6Vignola AM,Rennar SI,Hargreave FE,et al. Standardised methodology of sputum induction and processing. Future directions. Eur Respir J Suppl,2002,37:51s-55s.
  • 7Tsoumakidou M,Tzanakis N,Siafakas NM. Induced sputum in the investigation of airway inflammation of COPD. Respir Med,2003,97:863-871.
  • 8Vlachos-Mayer H,Leigh R,Sharon RF,et al. Success and safety of sputum induction in the clinical setting. Eur Respir J,2000,16:997-1000.
  • 9Rohde G,Wiethege A,Borg I,et al. Respiratory viruses in exacerbations of chronic obstructive pulmonary disease requiring hospitalisation:a case-control study. Thorax,2003,58:37-42.
  • 10王伟,徐少华,柳相珍,邵红艳.慢性阻塞性肺疾病急性发作期外周血及痰中IL-8和TNF-α测定的意义[J].现代免疫学,2004,24(1):63-65. 被引量:13

二级参考文献26

  • 1Pin I, Gibson PG, Kolendowicz R, et al. Use of induced sputum cell counts to investigate airway inflammation in asthma. Thorax,1992, 47: 25-29.
  • 2Pizzichini MM,Pizzichini E, Clelland L, et al. Sputum in severe exacerbations of sathma: kinetics of inflammatory indices after prednisone treatment. Am J Respir Crit Care Med, 1997, 155:1501-1508.
  • 3Ronchi MC, Piragino C, Rosi E, et al. Role of sputum differential cell count in detecting airway inflammation in patients with chronic bronchial asthma or COPD. Thorax, 1996,51:1000-1004.
  • 4Jatakanon A, Uasuf C, Maziak W, et al. Neutrophilic inflammation in seere persistent asthma. Am J Respir Crit Care Med.1999,160(5 Pt 1):1532-1539.
  • 5Takanashi S, Hasegawa Y, Kanehira Y, et al. Interleukin-10 level in sputum is reduced in bronchial asthma, COPD and in smokers. Eur Respir J, 1999,14:309-314.
  • 6Saetta M, Di Stefano A, Maestrelli P, et al. Airway eosinophilia in chronic bronchitis during exacerbations. Am J Respir Crit Care Med, 1994, 150 (6 Pt 1):1646-1652.
  • 7Bhowmik A, Seemungal TA, Sapsford RJ, et al. Relation of sputum inflammatory markers to symptoms and lung function changes in COPD exacerbations. Thorax, 2000, 55:114-120.
  • 8Crooks SW, Bayley DL, Hill SL, et al. Bronchial inflammation in acute bacterial exacerbations of chronic bronchitis: the role of leukotriene B4. Eur Respir J, 2000, 15:274-280.
  • 9Parameswaran K, Pizzichini E, Pizzichini MM, et al. Clinical judgment of airway inflammation versus sputum cell counts in patients with asthma. Eur Respir J, 2000, 15:486-490.
  • 10Jang AS, Choi IS. Eosinophil activation markers in induced sputum in asthmatics. Korean J Intern Med, 2000, 15: 1-7.

共引文献30

同被引文献383

引证文献45

二级引证文献277

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部